Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
SARS-CoV-2 NPro Inhibitor
SARS-CoV-2-IN-16 is a potent inhibitor of the SARS-CoV-2 nucleocapsid protein (NPro), demonstrating significant antiviral activity with an EC50 of 3.69 μM. This compound binds to NPro with a low KD value of 7.82 μM, indicating its efficacy as a high-affinity ligand. SARS-CoV-2-IN-16 is suitable for research applications focused on viral infection mechanisms and the development of therapeutic strategies against SARS-CoV-2. -
SARS-CoV-2 Inhibitor
SARS-CoV-2 3CLpro-IN-14 is an orally active inhibitor of the SARS-CoV-2 3CL protease (3CLpro), a crucial target for antiviral therapy. This compound exhibits robust anti-SARS-CoV-2 activity with an EC50 value of 0.18 μM while displaying low cytotoxicity with a CC50 greater than 50 μM in Vero E6 cells. It is applicable in the research of COVID-19 therapies, particularly for understanding viral replication mechanisms and testing potential antiviral compounds. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-19 is a potent inhibitor of SARS-CoV-2, specifically targeting the viral helicase nsp13 with an EC50 of 8.8 μM. This compound demonstrates strong anti-SARS-CoV-2 activity, making it a valuable tool for studying COVID-19 and other human coronavirus outbreaks. Its mechanism suggests applications in infectious disease research, particularly in the development of antiviral therapeutics. -
SARS-CoV Inhibitor
SARS-CoV-2-IN-99 is a potent inhibitor of the SARS-CoV-2 main protease, an essential enzyme for viral replication. This compound demonstrates significant antiviral activity, making it a valuable tool for research in the field of COVID-19 therapeutics. SARS-CoV-2-IN-99 can aid in studies aimed at developing effective antiviral strategies against SARS-CoV-2 and related coronaviruses. -
SARS-CoV-2 Inhibitor
N-0920 is a highly potent TMPRSS2 inhibitor, exhibiting an IC50 of 0.35 nM. This compound effectively inhibits the entry of SARS-CoV-2 variants EG.5.1 and JN.1 in Calu-3 cells, demonstrating remarkable picomolar EC50 values of 300 pM and 90 pM, respectively. N-0920 is an essential tool for research into viral entry mechanisms and therapeutic strategies against SARS-CoV-2. -
SARS-CoV Inhibitor
PLpro-IN-7 is a potent inhibitor of the papain-like protease (PLpro) of SARS-CoV, demonstrating an IC50 of 3 nM. This compound exhibits significant antiviral activity, making it a valuable tool in the study of SARS-CoV replication and pathogenesis. PLpro-IN-7 is essential for research focusing on the development of therapeutics targeting coronavirus infections. -
SARS-CoV-2 Inhibitor
3-Deazaguanosine is an antiviral compound targeting SARS-CoV-2, exhibiting a potent inhibitory effect with an EC50 value of 1.14 μM and a high CC50 exceeding 200 μM in Vero E6 cells. This reagent demonstrates significant potential in mitigating the severity of COVID-19 pneumonia, making it a valuable tool for research in viral pathogenesis and therapeutic development against coronavirus infections. -
SARS-CoV-2 Mpro Inhibitor
BFC204 is an inhibitor of the SARS-CoV-2 main protease (Mpro) that demonstrates a kinact/Ki value of 619 mol/s. This compound effectively disrupts the enzymatic activity of Mpro, which is essential for the viral replication process. BFC204 is utilized in research focused on antiviral drug development and the molecular mechanisms of SARS-CoV-2 pathogenesis. -
SARS-CoV-2 Viral Propagation Inhibitor
Covidcil-19 is a potent inhibitor targeting the frameshifting element (FSE) of SARS-CoV-2. By binding to the revised attenuator hairpin structure with a dissociation constant (Kd) of 11 nM, Covidcil-19 stabilizes its folded conformation, thereby impairing frameshifting efficiency. Importantly, it does not alter the RNA levels of the SARS-CoV-2 FSE. This compound serves as a valuable tool for investigating viral propagation mechanisms and presents potential applications in antiviral research against SARS-CoV-2. -
SARS-CoV-2 Mac1 Inhibitor
MDOLL-0229 is an antiviral reagent that targets the SARS-CoV-2 Mac1 protein, effectively repressing coronavirus replication. This compound demonstrates inhibitory activity against SARS-CoV-2 Mac1 with an IC50 value of 2.1 µM. MDOLL-0229 serves as a valuable tool for research applications focused on understanding SARS-CoV-2 pathogenesis and the development of antiviral strategies. -
SARS-CoV-2 Inhibitor
TKB272 is a selective antiviral agent targeting the main protease (Mpro) of SARS-CoV-2. It effectively inhibits the infection and replication of various SARS-CoV-2 strains, including Omicron variants, with an IC50 of 0.7 µM and an EC50 as low as 2.6 nM in cellular assays. Additionally, TKB272 demonstrates a high safety profile with a CC50 of 98 µM, indicating minimal cytotoxicity. Its ability to significantly reduce replication in transgenic mouse models highlights its potential as a valuable tool for SARS-CoV-2 research. -
SARS-CoV-2 E Protein Inhibitor
SARS-CoV-2-IN-117 is a potent inhibitor of the SARS-CoV-2 E protein, targeting its interaction with the host ZO-1 PDZ2 domain. This compound exhibits significant antiviral activity, effectively reducing viral replication. SARS-CoV-2-IN-117 is suitable for research applications focused on understanding and mitigating COVID-19. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-14 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro) with an IC50 of 0.044 μM. This compound demonstrates excellent water solubility and exhibits no cytotoxic effects, making it suitable for in vitro studies. SARS-CoV-2 Mpro-IN-14 is valuable for research applications focusing on COVID-19 and the development of antiviral therapeutics. -
SARS-CoV-2 main protease (Mpro) Inhibitor
UAWJ246 is a covalent reversible inhibitor targeting the SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of 0.045 μM and a Ki of 0.036 μM. This compound demonstrates significant antiviral activity by effectively inhibiting SARS-CoV-2 viral replication while maintaining low cytotoxicity. UAWJ246 is suitable for research focused on SARS-CoV-2 infection and the development of therapeutic strategies for COVID-19. -
SARS-CoV Inhibitor
SARS-CoV-2-IN-82 is a selective inhibitor targeting the programmed -1 ribosomal frameshift (PRF) mechanism in SARS-CoV-2. This compound effectively disrupts viral protein translation, thereby hindering the replication of the virus. It is primarily utilized in research applications focused on understanding the mechanisms of SARS-CoV-2 infection and developing antiviral strategies. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-89 is a potent inhibitor targeting SARS-CoV-2. This compound enhances interferon type I (IFN-I) responses in A549.hACE2 cells upon viral infection, making it a valuable tool for studying antiviral mechanisms and developing therapeutic strategies against COVID-19. Its application in research facilitates a deeper understanding of the immune response to SARS-CoV-2. -
SARS-CoV-2 Inhibitor
PB49673382 is a potent inhibitor of SARS-CoV-2, demonstrating significant antiviral activity. It effectively inhibits viral replication and mitigates the cytopathic effects associated with the virus, with an IC50 value of 6.42 μM. This compound is useful for research applications focused on understanding SARS-CoV-2 biology and developing therapeutic strategies against COVID-19. -
SARS-CoV-2 3CLpro Inhibitor
DB12055 is a covalent inhibitor targeting the 3CL protease of SARS-CoV-2. It demonstrates significant inhibitory activity against this viral protease, making it a valuable tool for research focused on COVID-19. Additionally, DB12055 may be useful for investigating metabolic disorders such as dyslipidemia and diabetes mellitus. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-30 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), with an IC50 value of 9.1 nM. This compound is critical for the study of SARS-CoV-2 biology and can be utilized in research focused on antiviral drug discovery and development. Its efficacy in inhibiting viral replication makes it a valuable tool for investigating therapeutic strategies against COVID-19. -
SARS-CoV-2 Mpro Inhibitor
BFC220 is a covalent inhibitor of SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of 2.77 μM. This compound is valuable for antiviral research, specifically in studies involving the inhibition of viral protease activity and the development of targeted therapies against COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-52 is a potent inhibitor targeting the SARS-CoV-2 virus, exhibiting an inhibitory potency characterized by a pIC50 of 0.3187. This compound demonstrates significant antiviral activity and is suitable for research applications aimed at understanding and mitigating SARS-CoV-2 infections. Its mechanisms may provide valuable insights into therapeutic strategies against COVID-19. -
SARS-CoV-2 Nsp12 Inhibitor
Nsp12-IN-2 is a SARS-CoV-2 Nsp12 inhibitor, specifically targeting the RNA-dependent RNA polymerase (RdRp) activity of the Nsp12-Nsp7-Nsp8 complex. This compound terminates RNA synthesis and inhibits the RNAylation and NMPylation of Nsp9. Nsp12-IN-2 shows potential for research into SARS-CoV-2 infections, as well as studies involving other coronaviruses and RNA viruses. -
SARS-CoV Inhibitor
SARS-CoV-2 Mpro-IN-51 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro) with an IC50 of 26 nM. This compound effectively targets the triple mutant variant L50F/E166A/L167F, making it a valuable tool for research into viral pathogenesis and therapeutic interventions. Its application extends to studies aimed at elucidating mechanisms of viral infection and drug resistance in SARS-CoV-2. -
SARS-CoV-2 3CL Protease Inhibitor
SARS-CoV-2 3CLpro-IN-33 is a potent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 1.5 nM. This compound demonstrates strong antiviral activity against SARS-CoV-2 in HEK293T-AT cells, with an EC50 of 0.017 μM. SARS-CoV-2 3CLpro-IN-33 is suitable for research applications focused on understanding COVID-19 infection and developing therapeutic strategies. -
SARS-CoV-2 Inhibitor
SARS-CoV-2 PLpro-IN-1 is a non-covalent, competitive inhibitor specifically targeting the SARS-CoV-2 PLpro enzyme. It demonstrates significant biological activity with an IC50 of 15.06 μM and a Ki value of 22.93 μM. Furthermore, SARS-CoV-2 PLpro-IN-1 effectively inhibits the proliferation of Vero cells, exhibiting an IC50 of 7.47 μM. This compound is suitable for research applications focused on viral inhibition and understanding the mechanisms of SARS-CoV-2 replication. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-67 is a vitamin K derivative that serves as an inhibitor of SARS-CoV-2. It exhibits significant antiviral activity against SARS-CoV-2, with an EC50 of 64.8 μM in VeroE6/TMPRSS2 cells. This compound specifically targets and inhibits the activity of SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), making it a valuable reagent for research applications in virology and the study of coronavirus infections. -
SARS-CoV-2 Inhibitor
Jobosic acid is a saturated fatty acid that functions as a selective inhibitor of SARS-CoV-2. It effectively inhibits the main protease (Mpro) and the spike receptor binding domain (RBD) interaction with ACE-2, demonstrating IC50 values of 7.5 μg/mL and 3 μg/mL, respectively. Jobosic acid also exhibits inhibitory effects on viral entry for the omicron variant of SARS-CoV-2, making it a valuable compound for research in antiviral therapies. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-69 is a non-covalent inhibitor specifically targeting the SARS-CoV-2 main protease (Mpro) with an EC50 value of 7.4 μM. This compound demonstrates potent inhibitory activity against Mpro and also acts as a non-covalent inhibitor of papain-like protease (PLpro). It is suitable for studies aimed at understanding the mechanisms of SARS-CoV-2 replication and for the development of antiviral therapeutics. -
SARS-CoV-2 Mac1-ADP-ribose Inhibitor
F594-1001 is a selective inhibitor of the SARS-CoV-2 Mac1-ADP-ribose activity, demonstrating IC50 values of 8.5 μM, 68 μM, and 45 μM in AS, FP, and FRET assays, respectively. This compound directly interacts with the Mac1 enzyme, resulting in dose-dependent inhibition of ADP-ribosylhydrolase activity. F594-1001 is valuable for research focused on understanding SARS-CoV-2 biology and developing therapeutic strategies against COVID-19. -
SARS-CoV-2-specific Entry Inhibitor
SARS-CoV-2-IN-120 is a specific entry inhibitor targeting the SARS-CoV-2 spike protein. By binding to and trimerizing within the apex cavity of the spike trimer, it effectively blocks the interaction between the receptor-binding domain (RBD) and ACE2. This compound demonstrates potent neutralization against the BA.2 lineage and subsequent Omicron variants, and has shown capabilities in inhibiting SARS-CoV-2 replication in murine models. SARS-CoV-2-IN-120 is valuable for research applications focused on viral entry mechanisms and therapeutic development against COVID-19. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-46 is an inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of approximately 25 μM. This compound demonstrates significant antiviral activity with low cytotoxicity, as indicated by an IC50 value of 7.4 μM against SARS-CoV-2. SARS-CoV-2 Mpro-IN-46 is suitable for research applications focused on understanding and combating coronavirus infections, particularly in the context of COVID-19. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2 3CLpro-IN-21 is an irreversible and covalent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 of 0.03 µM. Additionally, it demonstrates activity against the SARS-CoV-1 3CLpro with an IC50 of 0.12 µM. This compound is valuable for investigative research into viral protease inhibition and potential therapeutic strategies against SARS-CoV-2 infections. -
SARS-CoV-2 Papain-like Protease Inhibitor
SARS-CoV-2-IN-106 is a potent inhibitor of the SARS-CoV-2 papain-like protease (PLpro), demonstrating IC50 values of 0.44 μM for enzymatic activity and 0.18 μM for viral replication. This compound is crucial for research into SARS-CoV-2 infection mechanisms and for the development of antiviral therapies targeting protease enzymes. Its efficacy makes it a valuable tool for studying coronavirus biology and potential treatments. -
SARS-CoV-2 PLpro/Mpro Inhibitor
SARS-CoV-2-IN-68 is a covalent inhibitor targeting the SARS-CoV-2 PLpro and Mpro proteases. This compound exhibits significant antiviral activity by binding to the Zn-finger domain of PLpro, thereby disrupting viral replication. It serves as a valuable tool in research focused on developing therapeutic strategies against SARS-CoV-2 infections. -
SARS-CoV-2 PLpro Inhibitor
9-Aminominocycline is a potent inhibitor of the SARS-CoV-2 papain-like protease (PLpro), effectively disrupting its deubiquitination and protease activities with IC50 values of 4.55 µM and 4.15 µM, respectively. This compound demonstrates antiviral activity against SARS-CoV variants, including Delta and Omicron, with IC50 values of 1.04 µM and 2.35 µM in Calu-3 cells. It is a valuable research tool for investigating therapeutic strategies against SARS-CoV-2 and related coronaviruses. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-92 is a potent inhibitor specifically targeting SARS-CoV-2 variants, with an EC50 value of 0.48 μM. This compound also exhibits inhibitory activity against SARS-CoV and MERS-CoV, demonstrating its broad-spectrum antiviral potential. SARS-CoV-2-IN-92 selectively blocks the interaction with the estrogen receptor alpha (ERα-Glu II), highlighting its relevance in research applications focused on viral inhibition and receptor modulation. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-52 is a potent inhibitor of the SARS-CoV-2 main protease (MPro), demonstrating an EC50 of 0.0099 µM. It exhibits broad-spectrum antiviral activity against other coronaviruses, including MERS, OC43, and 229E, with EC50 values of 0.00961 µM, 0.138 µM, and 0.117 µM, respectively. This compound is suitable for research applications focusing on the development of antiviral therapeutics for COVID-19 and related viral infections. -
HCV/SARS-CoV-2 Inhibitor
Bemnifosbuvir is a potent inhibitor of Hepatitis C virus (HCV) replication with demonstrated efficacy against SARS-CoV-2. This orally active compound exhibits significant antiviral activity in vitro, achieving an effective concentration (EC90) of 0.47 μM against COVID-19. Bemnifosbuvir displays pangenotypic activity, making it a valuable tool for research into antiviral therapies for both HCV and SARS-CoV-2 infections. -
HCV/SARS-CoV-2 Inhibitor
Bemnifosbuvir hemisulfate is a potent inhibitor of HCV viral replication and a promising antiviral agent against SARS-CoV-2. This guanosine nucleotide proagent exhibits significant efficacy in vitro, demonstrating an EC90 value of 0.47 μM against COVID-19. Bemnifosbuvir hemisulfate also shows pangenotypic antiviral activity, making it a valuable tool for research in viral infections and therapeutic development. -
PPT1 Inhibitor
Ezurpimtrostat (hydrochloride) is a potent and selective PPT1 inhibitor with multiple biological activities. It disrupts lysosomal function, modulates autophagy, and induces apoptosis, making it a valuable tool in cancer research and immunology. This compound has demonstrated efficacy in reducing inflammatory markers such as IFN-α and CRP, as well as in lowering viral loads of SARS-CoV-2. Ezurpimtrostat is suitable for investigating conditions such as systemic lupus erythematosus, hepatocellular carcinoma, fibrosis, and other related disorders. -
RdRp inhibitor
Galidesivir hydrochloride (BCX 4430 hydrochloride) is a viral RNA-dependent RNA polymerase (RdRp) inhibitor; demonstrated broad-spectrum activity in multiple viruses and a favorable preliminary preclinical safety profile. -
S100A9 inhibitor
Paquinimod is a S100A9 inhibitor, which prevents S100A9 binding to TLR-4. -
SARS-CoV PLpro Inhibitor
4'-O-Methylbavachalcone is a prenylated flavonoid that acts as an inhibitor of the SARS-CoV papain-like protease (PLpro), displaying an IC50 value of 10.1 μM and a Ki of 4.6 μM. This compound has demonstrated the ability to inhibit poly (ADP-ribose) polymerase-mediated cell death and reduce cerebral infarct volume. Additionally, it modulates SUCNR1 activity and interferes with ERK1/2 signaling pathways, affecting cardiomyocyte hypertrophy. 4'-O-Methylbavachalcone is applicable in research focused on ischemic stroke, SARS-CoV, and cardiovascular diseases. -
SARS-CoV-2 RdRp Inhibitor
RdRP-IN-10 is a selective inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), exhibiting an IC50 of 5.78 μM. This compound covalently binds to Cys114 of the SARS-CoV-2 nsp8 protein, disrupting the stabilizing interactions between nsp8 and nsp12. RdRP-IN-10 effectively inhibits RNA polymerization mediated by RdRp without interfering with the RNA-RdRp complex formation. It demonstrates antiviral activity in cellular models and serves as a valuable tool for researching SARS-CoV-2 infection mechanisms and potential therapeutic interventions. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-115 is a potent inhibitor of SARS-CoV-2, demonstrating significant antiviral activity in infected Calu-3 cells with an EC50 of 1.7 μM. This compound effectively inhibits human dihydroorotate dehydrogenase (HsDHODH) with an IC50 of 1.5 μM. Notably, SARS-CoV-2-IN-115 preserves immune response without exhibiting antiproliferative effects on CD4 T cells, making it a valuable tool for research in antiviral therapeutics and immune modulation.
